About Thrive Earlier Detection
Thrive Earlier Detection is a company based in Cambridge (United States) founded in 2019 was acquired by Exact Sciences in October 2020. Thrive Earlier Detection has raised $367 million across 3 funding rounds from investors including Exact Sciences, Intermountain Healthcare and Brown Advisory. The company has 138 employees. Thrive Earlier Detection operates in a competitive market with competitors including Guardant Health, GRAIL, Natera, Foundation Medicine and ArcherDX, among others.
- Headquarter Cambridge, United States
- Employees 138
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website thrivedetect.com
- Social LinkedIn X
- Acquired by Exact Sciences (Oct 2020)
- Legal Name Thrive Earlier Detection Corp
- Total Equity Funding$367M (USD)
in 3 rounds
- Latest Funding Round$257M (USD), Series B
Jul 2020
- InvestorsExact Sciences
& 20 more
- Employee Count138
- Acquired byExact Sciences
(Oct 2020)
Funding Insights of Thrive Earlier Detection
Thrive Earlier Detection has successfully raised a total of $367M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $257 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $367M
- Total Rounds 3
- Last Round Series B — $257M
- First Round $110M
(May 2019)
- Investors Count 21
All 3 funding rounds of Thrive Earlier Detection with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2020 | $257M | Series B | – | Casdin Capital, S32 | |
| Jul 2019 | $2.2M | Grant | – | – | |
| May 2019 | $110M | Series A | – | Third Rock Ventures |
21 investors in total: 21 institutional.
Investors in Thrive Earlier Detection
Thrive Earlier Detection has secured backing from 21 investors, including venture fund and institutional investors. Prominent investors backing the company include Exact Sciences, Intermountain Healthcare and Brown Advisory.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are focused on pharmaceutical, biotechnology, and medical sectors. | – | baincapitallifesciences.com | Boston, United States | |
Investing in Life Sciences sectors like Healthcare and Biotechnology. | – | casdincapital.com | - | |
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
Seed and early-stage technology companies are funded by Lux Capital. | – | luxcapital.com | Menlo Park, United States | |
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Early-stage and late-stage biotech and finance companies are funded. | – | rockspringscapital.com | Baltimore, United States | |
Tech startups are funded by S32, a venture capital entity. | – | s32.com | Sunnyvale, United States | |
Venture capital funding is provided to early-stage life science companies. | – | thirdrockventures.com | Boston, United States | |
Early-stage tech and life sciences focused VC firm investing primarily in the US | – | biomaticscapital.com | Seattle, United States | |
Long-term private equity investments in transformational opportunities are pursued. | – | invus.com | New York, United States |
Investor details for Thrive Earlier Detection
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Thrive Earlier Detection
636 people are tracked at Thrive Earlier Detection (188 in leadership, 9 in board & advisors, 439 in team); the tracked headcount is 138.
| Name | Role | Group |
|---|---|---|
Michelle Beidelschies | Medical Affairs Director, Multi-cancer Early Detection - Thrive | Leadership |
Isaac Kinde | VP Technology Assessment | Leadership |
Anurag Gupta | Director, APAC - Indirect Markets | Leadership |
Jessica Angelos Castro | Emerging Capabilities, Strategic Innovation, And Partnerships- Growth Initiatives, Senior Director | Leadership |
Kevin Conroy | Chairman & CEO | Leadership |
Kristin Lamont | Director Medical Education & Information | Leadership |
Alex S. | Associate Director, International Accounting | Leadership |
Mark Hollenbeck | Associate Director, Enterprise Data | Leadership |
Patrick Tibbetts | Associate Director Of Data Engineering | Leadership |
Amir Khan | Chief Information Security Officer | Leadership |
Raj Pudipeddi | Chief Growth Officer | Leadership |
Sean Rollins | Director, IT Business Relationship Management - R&d And Corporate Strategy | Leadership |
Whitney Rusch | Director, Enterprise Platforms | Leadership |
Roman Mey | Director – Global IT Support Center Services | Leadership |
Courtney Cerdena | Sr. Director Of IT Solution Delivery | Leadership |
Matt Ford | Senior Director, Commercial Performance And Training | Leadership |
Rebeca Monsma | Principal Human Resources Business Partner | Leadership |
Bradley Arrick | Director, Oncology Medical Development | Leadership |
Eric Gagne | Lab Director | Leadership |
Bryan Maring | Director, Global Compliance Policy & Training | Leadership |
616 more people are available in the full profile.
Complete people profiles for Thrive Earlier Detection
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Thrive Earlier Detection
4 dated milestones of Thrive Earlier Detection across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Thrive Earlier Detection is founded.
- Funding First funding round of $110.0M.
- Funding Latest funding round, Series B, of $257.0M.
- Exit Acquired by Exact Sciences.
Competitors of Thrive Earlier Detection
Thrive Earlier Detection operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, GRAIL, Natera, Foundation Medicine and ArcherDX, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| grail.com | 2016 | Menlo Park, United States | $3.22B | 491 | Circulating tumor DNA is screened for early cancer detection. | |
| natera.com | 2004 | Redwood, United States | $152.1M | 3,293 | Developer of cell-free DNA testing for oncology, women’s health, and organ health | |
| foundationmedicine.com | 2010 | Cambridge, United States | $96.5M | 1,707 | Genomics-based diagnostic tests for cancer are provided. | |
| archerdx.com | 2013 | Boulder, United States | $152.6M | 429 | Molecular cancer diagnostic products are developed using patented AMP technology. | |
| strandls.com | 2000 | Bengaluru, India | $34.88M | 532 | Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery | |
| prenetics.com | 2009 | Hong Kong, China | $67.65M | – | Health risks are identified through online genetic and diagnostic testing. | |
| veracyte.com | 2008 | San Francisco, United States | $67.9M | 815 | Genomics-based diagnostic tests for cancer are developed. |
Detailed competitors of Thrive Earlier Detection
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Thrive Earlier Detection
Complete news archive for Thrive Earlier Detection
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Thrive Earlier Detection
10 companies that operate in the same segment as Thrive Earlier Detection (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Thrive Earlier Detection
Thrive Earlier Detection was founded in 2019.
Thrive Earlier Detection is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Thrive Earlier Detection is a funded company, having raised a total of $367M across 3 funding rounds to date. The company's 1st funding round was a Series A of $110M, raised on May 2019.
Thrive Earlier Detection has 138 employees.
Thrive Earlier Detection was founded in 2019 and is based in Cambridge, United States. Operations center on the biotechnology sector, where a blood-based liquid biopsy test is developed for detecting multiple cancers. DNA mutations and protein abnormalities associated with cancer are analyzed through this test. The approach supports treatment by enabling earlier identification in clinical settings.
Thrive Earlier Detection's top competitors include Guardant Health, GRAIL and Strand Life Sciences.
Thrive Earlier Detection has 21 investors. Key investors include Exact Sciences, Intermountain Healthcare, Brown Advisory, T. Rowe Price, and HHS.
Thrive Earlier Detection operates through Thrive Earlier Detection Corp.
Yes. Thrive Earlier Detection was acquired by Exact Sciences in October 2020.